Leadership

For the necessary data for your NDA, ANDA, or 505(b)(2) NDA submission, you can count on Camargo's end-to-end drug development and regulatory expertise. Our executive team are accomplished leaders in the full spectrum of drug development (pre-clinical, manufacturing, clinical, regulatory and commercial) and have extensive experience working in and with pharmaceutical, biotech and contract services organizations. Our practical knowledge of both the science and the business strategy of drug development streamlines the drug's path-to-market.

 

Kenneth V. Phelps
President/CEO

 

Ruth E. Stevens, Ph.D., MBA
Chief Scientific Officer, Executive Vice President

 

Lynn Gold, Ph.D.

Vice President of CMC Services

 

Ray Dawkins, M.D.

Chief Medical Officer

 

William P. Stoltman, J.D.
Senior Director, Regulatory Affairs and Quality Assurance

 

Stacey A. Ayres, Ph.D.
Director, Scientific Research Services

 

Cynthia F. Phurrough
Director, Clinical Services